Bioclinica

Biotech is one of the sectors where M&A activities never stop, as the potential for growth and development is immense. After the termination of a $160 billion merger with Allergan plc Ordinary Shares (NYSE: AGN), Pfizer Inc. (NYSE: PFE) has returned to the M&A table with a bang. Although...